Adenoviral vector with shield and adapter increases tumor specificity and escapes liver and immune control.
Schmid, M., Ernst, P., Honegger, A., Suomalainen, M., Zimmermann, M., Braun, L., Stauffer, S., Thom, C., Dreier, B., Eibauer, M., Kipar, A., Vogel, V., Greber, U.F., Medalia, O., Pluckthun, A.(2018) Nat Commun 9: 450-450
- PubMed: 29386504 
- DOI: 10.1038/s41467-017-02707-6
- Primary Citation of Related Structures:  
5OGI, 6EQC - PubMed Abstract: 
Most systemic viral gene therapies have been limited by sequestration and degradation of virions, innate and adaptive immunity, and silencing of therapeutic genes within the target cells. Here we engineer a high-affinity protein coat, shielding the most commonly used vector in clinical gene therapy, human adenovirus type 5 ...